SecBot SecBot
S-1/A ·Filed May 29, 2026

HLYK

HealthLynked Corp
BEARISH
Impact 7/10
Horizondays Processed5mo ago SEC0001213900-26-062879
IPO registration amendment
Actionable Insight ▼ Bearish

This is a distressed capital raise. The $4-$6 offering price is far above the $2.22 market price, signaling desperation. Expect heavy selling pressure post-pricing as the price adjusts lower. The concurrent resale registration of 150K shares from Evergreen Capital adds further overhang. The company's future depends on this offering closing and Nasdaq listing approval — both are uncertain. Avoid until price discovery settles.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
HLYK ▲ +23.87% at T+60d
SHORT call ✗ call lost -23.87% · α vs SPY -22.64% · entry $2.22 → $2.75
Entry = T+0 close
May 29, 2026
via day close
T+1d
+5.72%
call -5.72% · α -5.58%
$2.35
settled 5mo ago
T+5d
+39.64%
call -39.64% · α -42.39%
$3.10
settled 5mo ago
T+20d
+35.14%
call -35.14% · α -36.43%
$3.00
settled 4mo ago
T+60d
+23.87%
call -23.87% · α -22.64%
$2.75
settled 2mo ago

Executive Summary

HealthLynked is attempting a life-saving $7M IPO to move from the OTCQB to Nasdaq, but at a massive 83% premium to the last trade of $2.22. The company has a going-concern warning, burned through cash, and is offering shares at $4-$6 when the stock is at $2.22. The filing also registers 150,000 resale shares from a distressed convertible note holder.

Key Financial Metrics

Price Range
$4.00-$6.00 per share
Rev Growth
-45.0%

Key Facts

  • Offering up to 1,750,000 shares at $4-$6, but last trade was $2.22 on May 28 (53%+ discount).
  • Expected net proceeds of ~$6.16M after underwriting and expenses.
  • Going-concern warning: only $23,973 cash, $6.66M working capital deficit, $52.2M accumulated deficit as of March 31, 2026.
  • Total revenue collapsed 45% YoY to $423K in Q1 2026, with patient service revenue down 44%.
  • Net loss widened 54% to $1.62M in Q1 2026 vs $1.05M a year ago.
  • Concurrent resale registration of 150K shares from Evergreen Capital (convertible note holder) adds overhang.
  • CEO controls 99.3% of voting power; $6.48M related-party debt (February 2026 Dent Note).
  • Multiple material weaknesses in internal controls.

Financial Impact

$7M gross offering at 53-63% premium to market; dilution of ~48% to existing holders

revenuedilutionequitycash

Risk Factors

  • Offering may not close if Nasdaq listing is denied.
  • Severe dilution (48%) and massive premium to market price.
  • Going concern risk — cash runway measured in weeks without this offering.
  • Concurrent resale of 150K shares compounds selling pressure.
  • CEO has 99.3% voting control; governance concerns.

Market Snapshot

Exchange
OTC
Sector
Services-Offices & Clinics of Doctors of Medicine

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
S-1/A Filing (Primary)0001213900-26-062879
Document: ea029220401ex23-1.htm0001213900-26-062879
Document: 0001213900-26-062879-index-headers.html0001213900-26-062879
Document: 0001213900-26-062879-index.html0001213900-26-062879
Document: 0001213900-26-062879.txt0001213900-26-062879

US Market Status

Market Closed — Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 29, 2026